A seven-year survey of susceptibility to marbofloxacin of pathogenic strains isolated from pets

Meunier, Danièle; Acar, J. F.; Martel, Jean-Louis; Kroemer, S.; Vallé, Michel

doi:10.1016/j.ijantimicag.2004.09.004

Cited by 47 publications

(33 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…La aplicación intramuscular de 2 mg/kg de marbofloxacina genera concentraciones plasmáticas inmediatas que subsisten hasta las 24 h posaplicación y exceden la CMI requerida por los patógenos gramnegativos relevantes (13,14), excepto de Pseudomonas spp. (13); esto es similar a lo observado tras la aplicación de idéntica dosis intravenosa (9), oral o subcutánea (17).…”

Section: Discussionunclassified

“…Las características de persistencia y difusión tisular, sumadas a sus atributos microbiológicos (13,14), inclusive al efecto posantibiótico comprobado con las fluoroquinolonas (1,23) y al análisis del cociente predictor de eficacia establecido para fluoroquinolonas de ABC/CMI ≥ 125 h (24,25), sugieren la aplicación de este antimicrobiano en presencia de cepas patógenas que exhiben una CMI ≤ 0,15 μg/ml (13,14). En contraste, el predictor ABC/CMI es insuficiente para tratar infecciones causadas por Pseudomonas spp., en coincidencia con Frazier y colaboradores (11), según la CMI encontrada frente a este patógeno (13).…”

Section: Discussionunclassified

“…El t½β obtenido excede los hallados con enrofloxacina, difloxacina y orbifloxacina (11)(12)(13)(14)(15)(16). Se informaron valores de t½β para la vía oral de 9,07 ± 1,9 h (16), de 10,89 ± 0,84 h (11) y de 14,0 ± 4,9 h (17); de 8,08 ± 6,25 h (15) y de 12,4 ± 2,6 h (17), para la vía endovenosa, y de 7,51 ± 3,7 (15), para la aplicación intramuscular.…”

Section: Introductionunclassified

See 2 more Smart Citations

Evaluation of the contribution of gyrA mutation and efflux pumps to fluoroquinolone and multidrug resistance in pathogenic Escherichia coli isolates from dogs and cats

Shaheen¹,

Boothe²,

Oyarzábal³

et al. 2011

ajvr

View full text Add to dashboard Cite

ResumenSe estudió la disposición plasmática y urinaria de marbofloxacina en caninos (n = 6) tras la aplicación intramuscular de 2 mg/kg. En distintos tiempos posadministración se tomaron muestras de sangre hasta las 24 h, y de orina solo en los caninos machos (n = 4) a las 4, 8, 12 y 24 h. Se realizó una extracción líquido-líquido del analito con agua, metanol y centrifugado a 13.500 r. p. m. a 4 °C. La separación y cuantificación se realizó por HPLC mediante la elusión isocrática en fase reversa, utilizando columna C-18, detector de fluorescencia a 295 nm de excitación y 490 nm de emisión y fase móvil compuesta por agua, acetonitrilo y trietilamina. Las concentraciones plasmáticas temporales se analizaron con el software no compartimental PK Solution 2.0. Los resultados conseguidos indican pronta absorción, rápida y amplia distribución. El Cl y los valores conseguidos de t½β y TMR indican lenta depuración y prolongada permanencia. El ensayo determinó concentraciones plasmáticas perdurables hasta 24 h, y que exceden la CMI de patógenos relevantes. El cociente ABC/ CMI indica eficacia frente a microorganismos con CMI ≤ 0,15 μg/ml. Las concentraciones urinarias de marbofloxacina son más significativas que las plasmáticas. No obstante, se requieren nuevos estudios que avalen su empleo con la dosis y vía de aplicación ensayada.Palabras clave: caninos, farmacocinética, marbofloxacina, plasma, orina. Plasma and urine pharmacokinetics of intramuscular marbofloxacin in canines AbstractPlasma and urinary disposition of marbofloxacin was studied in canines (n = 6) after intramuscular administration of 2 mg/kg. At different times post-administration, blood samples were collected until 24 h, and urine samples, only from male dogs (n = 4) at 4; 8; 12, and 24 h. Liquid-liquid extraction of analyte with water, methanol, and centrifugation at 13500 rpm at 4 °C were performed. Separation and quantification were made using HPLC by reverse phase isocratic elution with a C18 column, fluorescence detector at 295 nm excitation and 490 nm emission, and a mobile phase consisting of water, acetonitrile, and triethylamine. Temporary plasma concentrations were analyzed with non-compartmental PK Solution 2.0 software.

show abstract

Section: Discussionunclassified

Section: Introductionunclassified

See 1 more Smart Citation

Evaluation of the contribution of gyrA mutation and efflux pumps to fluoroquinolone and multidrug resistance in pathogenic Escherichia coli isolates from dogs and cats

Shaheen¹,

Boothe²,

Oyarzábal³

et al. 2011

ajvr

View full text Add to dashboard Cite

show abstract

“…Pseudomonas aeruginosa is a frequently isolated Gram-negative bacterium in veterinary practice, associated mainly with external otitis, deep pyoderma, keratoconjunctivitis, respiratory and urinary tract infections [1,2]. This bacterium can develop resistance rapidly against several antibiotics, even during the course of antimicrobial treatment [3,4].…”

Section: Introductionmentioning

confidence: 99%

“…183 P. aeruginosa strains isolated from the outer ear canal of dogs were investigated and they found that 93.4% were sensitive to marbofl oxacin [11]. 26.1% resistance ratio was reported [1] in P. aeruginosa strains isolated from otitis cases in dogs and cats. Our previous study indicated 23% resistance and 16% moderate susceptibility ratio among 56 isolates [12].…”

Section: Introductionmentioning

confidence: 99%

Evaluating synergy between marbofloxacin and gentamicin in Pseudomonas aeruginosa strains isolated from dogs with otitis externa

Jerzsele

Pásztiné-Gere

2015

Acta Microbiologica Et Immunologica Hungarica

View full text Add to dashboard Cite

The aim of this study was to determine antimicrobial susceptibility of Pseudomonas aeruginosa strains to marbofl oxacin and gentamicin, and investigate the possible synergistic, additive, indifferent or antagonistic effects between the two agents. P. aeruginosa strains can develop resistance quickly against certain antibiotics if used alone, thus the need emerges to fi nd synergistic combinations. A total of 68 P. aeruginosa strains isolated from dogs were examined. In order to describe interactions between marbofl oxacin and gentamicin the checkerboard microdilution method was utilized. The MICs (minimum inhibitory concentrations) for marbofl oxacin and gentamicin were in the range 0.25-64 mg/L and 0.25-32 mg/L, respectively. The combination of marbofl oxacin and gentamicin was more effective with a MIC range of 0.031-8 mg/L and a MIC 90 of 1 mg/L, compared to 16 mg/L for marbofl oxacin alone and 8 mg/L for gentamicin alone. The FIC (fractional inhibitory concentration) indices ranged from 0.0945 (pronounced synergy) to 1.0625 (indifference). Synergy between marbofl oxacin and gentamicin was found in 33 isolates. The mean FIC index is 0.546, which represents a partial synergistic/additive effect close to the full synergy threshold. In vitro results indicate that marbofl oxacin and gentamicin as partially synergistic agents may prove clinically useful in combination therapy against P. aeruginosa infections. Although marbofl oxacin is not used in the human practice, the interactions between fl uoroquinolones and aminoglycosides may have importance outside the veterinary fi eld.

show abstract

Fluoroquinolones

Giguère¹,

Dowling²

2013

Antimicrobial Therapy in Veterinary Medicine

View full text Add to dashboard Cite

A seven-year survey of susceptibility to marbofloxacin of pathogenic strains isolated from pets

Cited by 47 publications

References 5 publications

Evaluation of the contribution of gyrA mutation and efflux pumps to fluoroquinolone and multidrug resistance in pathogenic Escherichia coli isolates from dogs and cats

Evaluation of the contribution of gyrA mutation and efflux pumps to fluoroquinolone and multidrug resistance in pathogenic Escherichia coli isolates from dogs and cats

Evaluating synergy between marbofloxacin and gentamicin in Pseudomonas aeruginosa strains isolated from dogs with otitis externa

Fluoroquinolones

Contact Info

Product

Resources

About